Publications

Nature genetics

The DNA methylation landscape of advanced prostate cancer.

01-08-2020

Nature genetics

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

01-08-2020

Scientific reports

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

02-07-2020

Molecular cancer research : MCR

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

01-07-2020

Cancer research

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

15-05-2020

Nature cancer

Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.

01-05-2020

International journal of cancer

IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.

15-04-2020

Genes & development

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

01-02-2020

Endocrine-related cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

01-02-2020

Nature communications

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

23-01-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Cancer cell

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

09-12-2019

Journal of mammary gland biology and neoplasia

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

01-12-2019

Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019

Nature communications

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

06-11-2019

Key Publication

Nucleic acids research

A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.

10-10-2019

Journal of mammary gland biology and neoplasia

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

01-09-2019

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Key Publication

Journal of neuroendocrinology

Identification of mineralocorticoid receptor target genes in the mouse hippocampus.

01-08-2019

Endocrine-related cancer

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

01-05-2019

Breast cancer research and treatment

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

01-05-2019

Cancer cell

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

15-04-2019

Life science alliance

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

01-02-2019

JCI insight

Frequent clonal relations between metastases and non-index prostate cancer lesions.

24-01-2019

Nature communications

Integrative epigenetic taxonomy of primary prostate cancer.

21-11-2018

Molecular oncology

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

01-11-2018

Cancer letters

CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells.

01-11-2018

Endocrine-related cancer

Molecular underpinnings of enzalutamide resistance.

01-11-2018

Endocrine-related cancer

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond.

31-10-2018

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

01-10-2018

The Journal of pathology

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

01-09-2018

Cell reports

Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism.

21-08-2018

Molecular oncology

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

01-08-2018

Endocrine-related cancer

Androgen receptor moonlighting in the prostate cancer microenvironment.

01-06-2018

Life science alliance

ERα activity depends on interaction and target site corecruitment with phosphorylated CREB1.

01-06-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.

01-04-2018

Nature communications

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

02-02-2018

Oncogene

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

18-01-2018

Nature communications

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

30-11-2017

Oncotarget

Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.

15-08-2017

Lung cancer (Amsterdam, Netherlands)

Targeting BAP1: a new paradigm for mesothelioma.

01-07-2017

Endocrine-related cancer

A review of estrogen receptor/androgen receptor genomics in male breast cancer.

01-03-2017

Proceedings of the National Academy of Sciences of the United States of America

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

21-02-2017

Breast cancer research and treatment

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

01-02-2017

Molecular endocrinology (Baltimore, Md.)

The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

01-10-2016

Cancer research

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

01-07-2016

Urology case reports

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

01-07-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

Oncotarget

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

31-05-2016

Molecular cancer research : MCR

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

01-05-2016

The DNA methylation landscape of advanced prostate cancer.

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.

IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program.

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Identification of mineralocorticoid receptor target genes in the mouse hippocampus.

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Frequent clonal relations between metastases and non-index prostate cancer lesions.

Integrative epigenetic taxonomy of primary prostate cancer.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells.

Molecular underpinnings of enzalutamide resistance.

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond.

Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

Androgen receptor moonlighting in the prostate cancer microenvironment.

ERα activity depends on interaction and target site corecruitment with phosphorylated CREB1.

Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.

Targeting BAP1: a new paradigm for mesothelioma.

A review of estrogen receptor/androgen receptor genomics in male breast cancer.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

This site uses cookies